Chemotherapeutic strategies for renal cell carcinoma.
Metastatic renal cell carcinoma (RCC) is a disease that is highly resistant to systemic chemotherapy. Responses to combination chemotherapy have been reported in patients with collecting duct carcinoma and the sarcomatoid variant of renal cancer. Clinical trials combining chemotherapy with biologic response modifiers have not resulted in significant advances in the treatment of RCC. Patients with advanced local or metastatic RCC should be offered investigational therapeutic options. The identification of novel agents with significantly improved antitumor activity remains a high priority in the treatment of this disease.
Milowsky
Matthew I
MI
Division of Hematology/Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, 525 East 68th Street, ST-359, New York, NY 10021, USA.
Nanus
David M
DM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009362:Neoplasm Metastasis